<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821898</url>
  </required_header>
  <id_info>
    <org_study_id>H-27999</org_study_id>
    <secondary_id>36533</secondary_id>
    <nct_id>NCT01821898</nct_id>
  </id_info>
  <brief_title>Eosinophilic Esophagitis Clinical Therapy Comparison Trial</brief_title>
  <official_title>Eosinophilic Esophagitis Clinical Therapy Comparison Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eosinophilic Esophagitis (EoE) is a disorder in which a type of white blood cell (eosinophil)&#xD;
      involved in allergic reactions, enter and cover the walls of the esophagus (food pipe). As a&#xD;
      result, the esophagus becomes swollen and blocked making it difficult to swallow, and this&#xD;
      leads to heartburn. In severe cases it can lead to food getting stuck in the esophagus and&#xD;
      poor growth or weight loss in children&#xD;
&#xD;
      The main purpose of this research study is to compare the effectiveness of two different&#xD;
      types of treatment for EoE:&#xD;
&#xD;
        1. Oral viscous budesonide- which is a steroid medication that has been used to treat&#xD;
           asthma. Recently, it has been used as a therapy to treat the eosinophilic inflammation&#xD;
           in EoE, and&#xD;
&#xD;
        2. Specific food elimination.&#xD;
&#xD;
      The study will also be looking to see if a blood test is useful in following the progression&#xD;
      of EoE. Currently the only way to follow EoE is by repeating endoscopy, which is a more&#xD;
      &quot;invasive test.&quot;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a open label, randomized, prospective clinical trial comparing the efficacy of&#xD;
      a topical steroid preparation to an antigen (food) elimination diet.&#xD;
&#xD;
      A total of 40 participants will be recruited for this study that are positive for food&#xD;
      allergens. Study participants will be randomly assigned to treatments as described below, and&#xD;
      the duration of each treatment phase will be 16 weeks.&#xD;
&#xD;
      The subjects will be randomized to group A and B. Subject and study team will NOT be blinded&#xD;
      to the group assignments.&#xD;
&#xD;
      Group A will receive oral viscous budesonide at a dose of 1 or 2 mg daily depending on the&#xD;
      height.&#xD;
&#xD;
      Group B will receive an elimination diet (elimination of the foods the subject is allergic&#xD;
      to).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment was below expectation&#xD;
  </why_stopped>
  <start_date type="Actual">July 9, 2013</start_date>
  <completion_date type="Actual">September 24, 2018</completion_date>
  <primary_completion_date type="Actual">September 24, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Number of Eosinophils/High Powered Field</measure>
    <time_frame>16 weeks</time_frame>
    <description>The primary outcome will be the peak eosinophil/high powered field on repeat biopsy after the treatment phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey Score</measure>
    <time_frame>16 weeks</time_frame>
    <description>PedsQL total survey score to assess overall quality of life before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assess the subject's symptoms using the validated tool termed Pediatric Eosinophilic Esophagitis (EoE) Symptom Severity Module by measuring % of normal bolus transit swallow and % of normal peristaltic esophageal body contractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Studies</measure>
    <time_frame>Conclusion of study</time_frame>
    <description>Proteomic studies search for certain proteins in the blood that may be linked to active EoE. Immune analysis will help identify better methods for diagnosis, treatment, and prevention of immune system changes leading to diseases.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Positive for food allergy: Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Budesonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive for food allergy: Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elimination diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Budesonide</intervention_name>
    <description>This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day</description>
    <arm_group_label>Positive for food allergy: Group A</arm_group_label>
    <other_name>Steroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Elimination diet</intervention_name>
    <description>This group will receive an elimination diet</description>
    <arm_group_label>Positive for food allergy: Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Signed written informed consent and assent if applicable prior to performing any study&#xD;
             specific procedure.&#xD;
&#xD;
          2. Male or female subjects aged 3-17 years old.&#xD;
&#xD;
          3. Diagnosis of EoE within 2 months of enrollment (greater than or equal to 15&#xD;
             eosinophils per high powered field in both proximal or distal esophageal specimens).&#xD;
&#xD;
          4. Subjects who have failed at least a two month trial of proton pump inhibitor.&#xD;
&#xD;
          5. A female subject of childbearing potential who is or may become sexually active agrees&#xD;
             to routinely use contraception from the time of signing informed consent and assent&#xD;
             until 30 days from end of study.&#xD;
&#xD;
          6. Positive allergy testing on prick and/or patch testing.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Subjects who are responsive to at least a two month trial of a proton pump inhibitor.&#xD;
&#xD;
          2. Diagnosis of Inflammatory Bowel Disease or static encephalopathy.&#xD;
&#xD;
          3. Prior abdominal surgery and other organ disorder not including atopic diseases.&#xD;
&#xD;
          4. Previous esophageal surgical procedure.&#xD;
&#xD;
          5. Previous esophageal congenital disorders such as tracheal esophageal fistula and&#xD;
             esophageal atresia.&#xD;
&#xD;
          6. Positive for pregnancy.&#xD;
&#xD;
          7. Previous therapy within 6 weeks with oral or swallowed steroids or strict dietary&#xD;
             elimination of major allergens&#xD;
&#xD;
          8. Presence of increased eosinophils in the stomach, small intestine, large intestine,&#xD;
             and colon based on Debrosse et al.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla M. Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 27, 2013</study_first_submitted>
  <study_first_submitted_qc>March 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <results_first_submitted>February 5, 2020</results_first_submitted>
  <results_first_submitted_qc>December 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2021</results_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Carla McGuire Davis</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Eosinophil</keyword>
  <keyword>Reflux</keyword>
  <keyword>Esophagus</keyword>
  <keyword>Food allergy</keyword>
  <keyword>Trouble Swallowing</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 11, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT01821898/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Positive for Food Allergy: Group A</title>
          <description>Oral Budesonide&#xD;
Oral Budesonide: This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day. Children &lt; 10 years will receive 1 mg daily. Children 10 years and older will receive 2 mg daily.</description>
        </group>
        <group group_id="P2">
          <title>Positive for Food Allergy: Group B</title>
          <description>Elimination diet&#xD;
Elimination diet: This group will receive an elimination diet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Positive for Food Allergy: Group A</title>
          <description>Oral Budesonide&#xD;
Oral Budesonide: This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day.</description>
        </group>
        <group group_id="B2">
          <title>Positive for Food Allergy: Group B</title>
          <description>Elimination diet&#xD;
Elimination diet: This group will receive an elimination diet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EoE endoscopy score</title>
          <description>The range is 0-300 eosinophils per high powered field and higher numbers correlate with worse outcome. A diagnosis of EoE by endoscopic biopsy is demonstrated by intraepithelial eosinophilic infiltration (peak cell count ≥15 eosinophils/high power field [eos/hpf]).</description>
          <units>cells/high powered field</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Patient 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Number of Eosinophils/High Powered Field</title>
        <description>The primary outcome will be the peak eosinophil/high powered field on repeat biopsy after the treatment phase.</description>
        <time_frame>16 weeks</time_frame>
        <population>None of the enrolled participants had a repeat biopsy because they did not finish the trial due to undue stress and anxiety.</population>
        <group_list>
          <group group_id="O1">
            <title>Positive for Food Allergy: Group A</title>
            <description>Oral Budesonide&#xD;
Oral Budesonide: This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day. Children &lt; 10 years will receive 1 mg daily. Children 10 years and older will receive 2 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Positive for Food Allergy: Group B</title>
            <description>Elimination diet&#xD;
Elimination diet: This group will receive an elimination diet</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Number of Eosinophils/High Powered Field</title>
          <description>The primary outcome will be the peak eosinophil/high powered field on repeat biopsy after the treatment phase.</description>
          <population>None of the enrolled participants had a repeat biopsy because they did not finish the trial due to undue stress and anxiety.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey Score</title>
        <description>PedsQL total survey score to assess overall quality of life before and after treatment</description>
        <time_frame>16 weeks</time_frame>
        <population>None of the enrolled participants had a PedQL because they did not finish the trial due to undue stress and anxiety.</population>
        <group_list>
          <group group_id="O1">
            <title>Positive for Food Allergy: Group A</title>
            <description>Oral Budesonide&#xD;
Oral Budesonide: This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day</description>
          </group>
          <group group_id="O2">
            <title>Positive for Food Allergy: Group B</title>
            <description>Elimination diet&#xD;
Elimination diet: This group will receive an elimination diet</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey Score</title>
          <description>PedsQL total survey score to assess overall quality of life before and after treatment</description>
          <population>None of the enrolled participants had a PedQL because they did not finish the trial due to undue stress and anxiety.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Score</title>
        <description>Assess the subject's symptoms using the validated tool termed Pediatric Eosinophilic Esophagitis (EoE) Symptom Severity Module by measuring % of normal bolus transit swallow and % of normal peristaltic esophageal body contractions.</description>
        <time_frame>16 weeks</time_frame>
        <population>Pediatric Eosinophilic Esophagitis (EoE) Symptom Severity Module was not completed because the subjects did not finish the trial due to undue stress and anxiety.</population>
        <group_list>
          <group group_id="O1">
            <title>Positive for Food Allergy: Group A</title>
            <description>Oral Budesonide&#xD;
Oral Budesonide: This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day</description>
          </group>
          <group group_id="O2">
            <title>Positive for Food Allergy: Group B</title>
            <description>Elimination diet&#xD;
Elimination diet: This group will receive an elimination diet</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Score</title>
          <description>Assess the subject's symptoms using the validated tool termed Pediatric Eosinophilic Esophagitis (EoE) Symptom Severity Module by measuring % of normal bolus transit swallow and % of normal peristaltic esophageal body contractions.</description>
          <population>Pediatric Eosinophilic Esophagitis (EoE) Symptom Severity Module was not completed because the subjects did not finish the trial due to undue stress and anxiety.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exploratory Studies</title>
        <description>Proteomic studies search for certain proteins in the blood that may be linked to active EoE. Immune analysis will help identify better methods for diagnosis, treatment, and prevention of immune system changes leading to diseases.</description>
        <time_frame>Conclusion of study</time_frame>
        <population>Analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Positive for Food Allergy: Group A</title>
            <description>Oral Budesonide&#xD;
Oral Budesonide: This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day</description>
          </group>
          <group group_id="O2">
            <title>Positive for Food Allergy: Group B</title>
            <description>Elimination diet&#xD;
Elimination diet: This group will receive an elimination diet</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Studies</title>
          <description>Proteomic studies search for certain proteins in the blood that may be linked to active EoE. Immune analysis will help identify better methods for diagnosis, treatment, and prevention of immune system changes leading to diseases.</description>
          <population>Analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were not collected due to the termination of the study.</time_frame>
      <desc>Adverse events were not collected due to the termination of the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Positive for Food Allergy: Group A</title>
          <description>Oral Budesonide&#xD;
Oral Budesonide: This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day. Children &lt; 10 years will receive 1 mg daily. Children 10 years and older will receive 2 mg daily.</description>
        </group>
        <group group_id="E2">
          <title>Positive for Food Allergy: Group B</title>
          <description>Elimination diet&#xD;
Elimination diet: This group will receive an elimination diet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was terminated due to the inability of current subjects to complete the protocol and poor enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carla M. Davis, MD</name_or_title>
      <organization>Baylor College of Medicine/Texas Children's Hospital</organization>
      <phone>832-824-1319</phone>
      <email>carlad@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

